Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend

OBJECTIVE: Fracture risk increases with age, but few studies focus on persons ≥80 years. In the ACTIVE trial, treatment with abaloparatide for 18 months reduced osteoporotic fracture risk and increased bone mineral density. These effects were maintained with 24 months alendronate treatment in ACTIVE...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Menopause
Main Authors: Greenspan, Susan L., Fitzpatrick, Lorraine A., Mitlak, Bruce, Wang, Yamei, Harvey, Nicholas C., Deal, Chad, Cosman, Felicia, McClung, Michael
Formato: Artigo
Idioma:Inglês
Publicado: Lippincott Williams & Wilkins 2020
Assuntos:
Original Studies
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7515468/
https://ncbi.nlm.nih.gov/pubmed/32665529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/GME.0000000000001593
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares